Paul Tudor Jones’s Aldeyra Therapeutics ALDX Stock Holding History

Paul Tudor Jones’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,000	Closed	-$98.4K	–	3537
2025 Q4	$98.4K	Buy	+19,000	New	+$97.6K	﹤0.01%	3381

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Paul Tudor Jones's ALDX Position: Q4 2018 in Review

Paul Tudor Jones sold out of Aldeyra Therapeutics (ALDX) in Q4 2018, closing a stake of 14,000 shares — an estimated $193K sold.

Paul Tudor Jones first reported a position in ALDX in Q3 2018 and held it in 1 quarter. The position peaked at $193K in Q3 2018. 77 funds tracked by Wall St. Rank hold ALDX as of Q4 2018.

Paul Tudor Jones reported no remaining Aldeyra Therapeutics position as of Q4 2018 after selling out during the quarter.
Paul Tudor Jones sold 14,000 Aldeyra Therapeutics shares in Q4 2018, an estimated $193K.
Paul Tudor Jones first reported a position in Aldeyra Therapeutics in Q3 2018 and held it in 1 quarter.
Paul Tudor Jones's Aldeyra Therapeutics position peaked at $193K in Q3 2018.
77 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2018.

Based on Tudor Investment Corp's 13F filing for Q4 2018, filed 14 Feb 2019.